New Drugs Show Signs of Slowing Alzheimer’s
Another drug, called aducanumab, is still in the earliest stages of clinical testing. In those trials, researchers are still trying to determine the best dose to give people.
Similar to solanezumab, aducanumab showed slight benefits on tests of thinking and memory on the highest dose of the drug.
The differences were in the range of one to two points compared to placebo.
On that dose, though, about a third of people reported headaches, visual disturbances, and confusion.
Based on those results, Jeff Sevigny, MD, senior medical director of neurodegenerative disorders at Biogen, the company that’s developing the drug, said the company is already screening patients for longer and larger studies of the drug.
New Drugs Show Signs of Slowing Alzheimer’s
Slowing Alzheimer’s in Its Early Stages continued...
Another drug, called aducanumab, is still in the earliest stages of clinical testing. In those trials, researchers are still trying to determine the best dose to give people.
Similar to solanezumab, aducanumab showed slight benefits on tests of thinking and memory on the highest dose of the drug.
The differences were in the range of one to two points compared to placebo.
On that dose, though, about a third of people reported headaches, visual disturbances, and confusion.
Based on those results, Jeff Sevigny, MD, senior medical director of neurodegenerative disorders at Biogen, the company that’s developing the drug, said the company is already screening patients for longer and larger studies of the drug.
Source...